Amgen Inc. $AMGN Stake Lessened by Atria Investments Inc

Atria Investments Inc trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,447 shares of the medical research company’s stock after selling 4,625 shares during the quarter. Atria Investments Inc’s holdings in Amgen were worth $11,696,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. TAGStone Capital Inc. increased its holdings in Amgen by 0.8% in the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after buying an additional 32 shares during the last quarter. Wealth Quarterback LLC grew its position in shares of Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after acquiring an additional 34 shares in the last quarter. DDFG Inc increased its holdings in shares of Amgen by 1.1% in the 3rd quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock valued at $850,000 after acquiring an additional 34 shares during the last quarter. Nicholson Wealth Management Group LLC raised its position in shares of Amgen by 0.6% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after acquiring an additional 35 shares in the last quarter. Finally, LS Investment Advisors LLC lifted its stake in Amgen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock worth $250,000 after purchasing an additional 35 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 0.1%

NASDAQ:AMGN opened at $366.20 on Friday. The stock has a market cap of $197.19 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 3.75 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $385.12. The business has a fifty day moving average of $336.68 and a 200-day moving average of $313.14.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s payout ratio is 66.90%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. DZ Bank increased their price objective on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. BMO Capital Markets raised their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Oppenheimer set a $400.00 target price on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Finally, Cantor Fitzgerald raised their price target on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $354.04.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.76% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.